Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-828 20/1.25mg in Healthy Volunteers
NCT05881707Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan and Levamlodipine in hypertension (HTN) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration at 72 hour and Maximum Plasma Concentration at 72 hour. Started Jul 2023; status: completed.
02
Drugs
telmisartanLevamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05881707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881707.